期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 172, 期 18, 页码 4481-4492出版社
WILEY
DOI: 10.1111/bph.13233
关键词
-
资金
- Ministry Science and Technology of Taiwan [NSC101-2311-B-037-002-MY3, MOST103-2622-B-037-007-CC3]
- National Sun Yat-Sen University-KUM [NSYSU-KMU 103-I005, NSYSU-KMU 104-I011]
Background and PurposeThis study was designed to evaluate the effect of betulinic acid (BA), extracted from Avicennia marina, on the replication of hepatitis C virus (HCV) and to investigate the mechanism of this BA-mediated anti-HCV activity. Experimental ApproachHCV replicon and infectious systems were used to evaluate the anti-HCV activity of BA. Exogenous COX-2 or knock-down of COX-2 expression was used to investigate the role of COX-2 in the anti-HCV activity of BA. The effects of BA on the phosphorylation of NF-B and on kinases in the MAPK signalling pathway were determined. The anti-HCV activity of BA in combination with other HCV inhibitors was also determined to assess its use as an anti-HCV supplement. Key ResultsBA inhibited HCV replication in both Ava5 replicon cells and in a cell culture-derived infectious HCV particle system. Treatment with a combination of BA and IFN-, the protease inhibitor telaprevir or the NS5B polymerase inhibitor sofosbuvir resulted in the synergistic suppression of HCV RNA replication. Exogenous overexpression of COX-2 gradually attenuated the inhibitory effect of BA on HCV replication, suggesting that BA reduces HCV replication by suppressing the expression of COX-2. In particular, BA down-regulated HCV-induced COX-2 expression by reducing the phosphorylation of NF-B and ERK1/2 of the MAPK signalling pathway. Conclusions and ImplicationsBA inhibits HCV replication by suppressing the NF-B- and ERK1/2-mediated COX-2 pathway and may serve as a promising compound for drug development or as a potential supplement for use in the treatment of HCV-infected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据